$0.940.20(26.68%)
Bid: 0.9125 x 7000Ask: 0.94 x 1300
August 13, 2026 1:21 PMETVolume: 32,278,549
USDNASDAQ Capital MarketDelayed Price
Company Profile
Description & Contact Information
Business Description
BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies for cancers with high unmet need. Its lead asset, Plinabulin, has been studied in over 700 cancer patients and is in late-stage development across multiple cancer indications, with results published in The Lancet Respiratory Medicine. Plinabulin's novel mechanism as a GEF-H1 agonist with dendritic cell maturation benefit supports both anti-cancer activity and immune modulation, offering ...
Address
100 Campus Drive,West Side, 4th Floor, Suite 410, Florham Park, NJ, US, 07932
Telephone
+1 646 - 305-6387
Website
https://www.beyondspringpharma.com
I (Znewcar1) do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
I will not and cannot be held liable for any actions you take as a result of anything you read here.